{"id":"W4221092886","doi":"10.1016/j.esmoop.2022.100419","title":"Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Merck Sharp and Dohme; Genentech; Novartis Farmacéutica; Servier; Oncolytics Biotech; Else Kröner-Fresenius-Stiftung; Cancer Research UK; AstraZeneca España; Tessa Therapeutics; Eli Lilly and Company; Boehringer Ingelheim España; Novartis; Celgene; Roche España; F. Hoffmann-La Roche; Roche; NordForsk; Ernst Schering Foundation; GlaxoSmithKline España; Wilhelm Sander-Stiftung; Amgen; Pfizer; Bristol-Myers Squibb; Sanofi; MedImmune; Merck","keywords":"Medicine; Atezolizumab; Internal medicine; Clinical endpoint; Interim analysis; Hazard ratio; Lung cancer; Oncology; Surgery; Cancer; Confidence interval; Clinical trial; Gastroenterology; Pembrolizumab; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006831727,0.000160296,0.0005500162,0.0002090162,0.000224122,0.00001661394,0.0006710341,0.00003487603,0.002237116],"category_scores_gemma":[0.0001112576,0.0001596989,0.00005175953,0.0005669905,0.00006156642,0.0001201327,0.000757887,0.0004700786,0.000008962208],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001042762,"about_ca_system_score_gemma":0.0007204586,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.04076487,"about_ca_topic_score_gemma":0.00866337,"domain_scores_codex":[0.997814,0.0002044265,0.0004623233,0.0004571778,0.0006620917,0.0003999702],"domain_scores_gemma":[0.9989221,0.00008431572,0.0001109721,0.0006650889,0.00008050343,0.0001370377],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.04204327,0.04586055,0.3549044,0.0002188593,0.0008407053,0.001427363,0.06591828,0.02081599,0.02768619,0.00004117652,0.008383836,0.4318593],"study_design_scores_gemma":[0.4072911,0.09151485,0.1437735,0.0004207419,0.0001602352,0.00007509437,0.05664677,0.03533684,0.04884719,0.0001166123,0.2144314,0.001385654],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924663,0.0001289178,0.000006095487,0.0004543081,0.0001807819,0.004504402,0.00004262529,0.00002425249,0.002192283],"genre_scores_gemma":[0.9957134,0.00006977127,0.00034069,0.0002651875,0.00003678665,0.00182209,0.00002559768,0.00005245363,0.001673988],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4304737,"threshold_uncertainty_score":0.998675,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09255978133815697,"score_gpt":0.4642404448781073,"score_spread":0.3716806635399503,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}